Fusion Antibodies PLC (FAB) — Cash Flow Reinvestment Rate

Latest as of March 2022: 0.39x

Fusion Antibodies PLC (FAB) has a Cash Flow Reinvestment Rate of 0.39x as of March 2022, reinvesting GBX67.00K (capex GBX67.00K ) from operating cash flow of GBX174.00K. Check FAB cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.

Reinvestment Rate

0.39x

(Capex + Investments) / Operating CF

Total Reinvested

GBX67.00K

Capex + Investments

Operating Cash Flow

GBX174.00K

GBX

Capital Expenditures

GBX67.00K

GBX

Fusion Antibodies PLC Cash Flow Reinvestment Rate (2016–2018)

Historical reinvestment intensity for Fusion Antibodies PLC across 2 annual periods. Explore FAB cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.

Annual Cash Flow Reinvestment Rate for Fusion Antibodies PLC (2016–2018)

Year-by-year capital reinvestment analysis for Fusion Antibodies PLC. For live market cap and broader valuation context, see Fusion Antibodies PLC (FAB) total market value.

Year	Reinvestment Rate	Total Reinvested (GBX)	Operating CF	Capex	YoY Change
2018	11.52x	GBX889.19K	GBX77.19K	GBX444.60K	▲ +11063.6%
2016	0.10x	GBX35.76K	GBX346.57K	GBX35.76K	—

Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow